pharma · Gram-negative Bacterial Infections · SARS-CoV-2 Infection
Shionogi Inc. (U.S.)
Shionogi B.V.
Shionogi Inc. (U.S.) clinical programs — 6 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- Florham Park, USA
- Founded
- 2001
- Employees
- 601
- Programs
- 6
- Drugs
- 8
- Patents
- 0
Shionogi Inc. (U.S.) projects
6 ClinicalTrials.gov programs sponsored by Shionogi Inc. (U.S.).
Shionogi Inc. (U.S.) has 6 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
S-217622
Shionogi B.V.
SARS-CoV-2 Infection
1 trial -
S-268019-b
Shionogi B.V.
SARS-CoV-2
1 trial -
2402T1432
Shionogi B.V.
Respiratory Syncytial Virus
1 trial -
Cefiderocol
Shionogi B.V.
Gram-negative Bacterial Infections
1 trial -
S-337395
Shionogi B.V.
Respiratory Syncytial Virus Infections
1 trial -
S-606001 matching placebo, S-606001
Shionogi B.V.
Late-onset Pompe disease.
1 trial
Frequently asked questions
How many clinical projects does Shionogi Inc. (U.S.) have?
6 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.